Endo-Histo Foundational Fusion Model: A Novel Artificial Intelligence Approach for Predicting Histologic Remission and Early Response to Therapy in a Phase 2 Ulcerative Colitis Clinical Trial
Marietta Iacucci(University Hospitals Birmingham NHS Foundation Trust), Valery Naranjo(Universitat Politècnica de València), Valentina Vadori(London South Bank University), Enrico Grisan(University of Padua), Klaus Gottlieb, Brian Hayes(Cork University Hospital), Miguel Puga‐Tejada(University College Cork), R Crotty(Cork University Hospital), Ilaria Ditonno(University College Cork), Carolyn Owen(University of Calgary), Rocío del Amor(Universitat Politècnica de València), Giovanni Santacroce(Università Cattolica del Sacro Cuore), Umesh Chaudhari(Regeneron (United States)), I Zammarchi(APC Microbiome Institute), Davide Zardo(Ospedale San Bortolo), Bisi Bode Kolawole(London South Bank University), Subrata Ghosh(University College Cork), Yasuharu Maeda(University College Cork), Louise Burke(Cork University Hospital), Pascual José Claramonte Meseguer(Generalitat Valenciana), William Eastman(Eli Lilly (United States)), Alfredo Redondo Diéguez(Universitat Politècnica de València)
Cited by 0
Related Papers
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
|New England Journal of Medicine|2012|1.1k
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
|Journal of Crohn s and Colitis|2021|1.1k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907